4.3亿融资！植入式神经刺激器完成B轮

Core Viewpoint - The article discusses the advancements in migraine treatment, particularly focusing on the MySalvia Therapy system developed by Salvia BioElectronics, which aims to address unmet needs in chronic migraine management through innovative neurostimulation techniques [1][3][14]. Group 1: Company Overview - Salvia BioElectronics, founded in 2017 and headquartered in Eindhoven, Netherlands, specializes in minimally invasive neurostimulation technologies based on neuroanatomical mapping [14]. - The company has successfully raised a total of $105 million in funding, with the latest round being a $60 million Series B financing aimed at advancing its core product, MySalvia Therapy [1][14]. - The RECLAIM study, a multi-center randomized controlled trial for MySalvia Therapy, is expected to complete its first round of results by 2027 [14]. Group 2: Market Opportunity - Migraine is the second leading cause of disability globally, affecting over 1.06 billion people, with chronic migraine patients constituting approximately 10%-15% of this population [3]. - The economic burden of migraine exceeds $110 billion annually, highlighting a significant market opportunity for effective treatments [3]. - Despite advancements in oral preventive medications and biologics, there remains a strong demand for non-drug, personalized, and long-term effective treatment options for chronic migraine sufferers [3][13]. Group 3: MySalvia Therapy System - MySalvia Therapy involves the implantation of two ultra-thin electrodes targeting the trigeminal and occipital nerves to modulate nerve excitability and reduce the frequency and intensity of migraine attacks [4][10]. - The system has received FDA designation as a "Breakthrough Device" and is currently undergoing the RECLAIM registration trial, with early data showing a reduction in migraine days from 22 to 7 per month, significantly outperforming non-invasive devices [6][10]. - The dual-target approach of MySalvia Therapy aims to enhance control over migraine pathways, offering a differentiated solution in the neurostimulation market [10][15]. Group 4: Competitive Landscape - The non-invasive neurostimulation market for migraine has matured, with several FDA-approved devices available, including gammaCore, SAVI Dual, Nerivio, and Cefaly, which primarily target peripheral nerve stimulation [7][11][12]. - While these non-invasive devices are user-friendly and have low risks, they may not provide sufficient depth of treatment for severe chronic migraine patients, indicating a gap that MySalvia Therapy could fill [12][13]. - MySalvia Therapy's invasive nature and dual-target mechanism present a potential "high-level solution" for patients with unmet treatment needs, particularly those who do not respond to existing therapies [13].